| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/24/2003 | US20030139340 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
| 07/24/2003 | US20030139339 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor ( TFPI) |
| 07/24/2003 | US20030139334 Cell cycle controlling protein; vaccines |
| 07/24/2003 | US20030139330 Transcription factors containing two potential dna binding motifs |
| 07/24/2003 | US20030139328 Complexing; modulating biological activation |
| 07/24/2003 | US20030138932 Comprises enzymatic glycoproteins for use as antitumor/antiproliferative agents; enzyme inhibitors; drug screening |
| 07/24/2003 | US20030138931 Hydrolase polypeptide for dephosphorylating mitogen activated kinases (MAP-kinase); antiapoptosis; antiproliferative agents |
| 07/24/2003 | US20030138926 Novel polynucleotides and polypeptides encoded thereby |
| 07/24/2003 | US20030138916 Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
| 07/24/2003 | US20030138884 APRIL- a novel protein with growth effects |
| 07/24/2003 | US20030138866 Novel Osp-C derived peptide fragments |
| 07/24/2003 | US20030138862 Anti-HLA-DR antibodies and the methods of using thereof |
| 07/24/2003 | US20030138836 Detecting modulators of a silencing mediator for retinoic acid receptor; relieving suppression of steroid/thyroid hormone receptor activity; GAL4 DNA binding domains |
| 07/24/2003 | US20030138833 Psoriasin expression by breast epithelial cells |
| 07/24/2003 | US20030138832 Modulating insulin receptor signaling through targeting FACL |
| 07/24/2003 | US20030138818 G-protein coupled receptors |
| 07/24/2003 | US20030138815 Cyclic adenosine monophosphate (cAMP); drug screening; bronchodilators; antiinflammatory agents; immunomodulators; antiallergens; bioassays |
| 07/24/2003 | US20030138808 Polypeptides wherein epitopes correspond to proteosome cleavage product of tyrosinase and major histocompatability complex; vaccine |
| 07/24/2003 | US20030138769 Immunogenic HBc chimer particles having enhanced stability |
| 07/24/2003 | US20030138461 Process for the in vitro culture of different stages of tissular parasites |
| 07/24/2003 | US20030138459 Method of vaccination through serotype rotation |
| 07/24/2003 | US20030138458 HCV E1E2 vaccine compositions |
| 07/24/2003 | US20030138456 Vaccines expressed in plants |
| 07/24/2003 | US20030138455 Urogential or anorectal transmucosal vaccine delivery system |
| 07/24/2003 | US20030138454 Vaccination method |
| 07/24/2003 | US20030138453 Microparticles comprise a polymer such as a poly(alpha-hydroxy acid), polyhydroxy butyric acid, polycaprolactone, a polyorthoester, a polyanhydride, formed using cationic, anionic, or nomonic detergents; drug delivery |
| 07/24/2003 | US20030138452 Chemokine-tumor antigen fusion proteins as cancer vaccines |
| 07/24/2003 | US20030138451 Contacting a sample from the blood of a human or animal with the chimeric polypeptide and determining the presence of visceral Leishmaniosis by detection of binding between polypeptide and Leishmania infantum antibodies |
| 07/24/2003 | US20030138450 Plasmodium falciparum AMA-1 protein and uses thereof |
| 07/24/2003 | US20030138449 Method of administering FimH protein as a vaccine for urinary tract infections |
| 07/24/2003 | US20030138448 An immunogenic conjugate comprising a plurality of deacylated lipopolysaccharide molecules from a gram-negative bacterium covalently linked to gucosamine residue of D.discodideum proteinase 1 |
| 07/24/2003 | US20030138447 Derivatives of choline binding proteins for vaccines |
| 07/24/2003 | US20030138446 Nucleic acid vaccine to protect salmon against piscirickettsiosis salmonis a gramnegative bacteria |
| 07/24/2003 | US20030138445 gp41 antigen |
| 07/24/2003 | US20030138443 Cloning of chicken anemia virus DNA |
| 07/24/2003 | US20030138442 Protein- or polynucleic acid-based vaccine which protects a pig against porcine reporductive and respiratory syndrome |
| 07/24/2003 | US20030138440 Multimeric proteins and methods of making and using same |
| 07/24/2003 | US20030138438 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/24/2003 | US20030138436 Administering a vaccine containing an immonologically effective dose of Th1 type immune response inducing mycobacteria to the airways of asthma patient for reducing severity and risk of developing asthma |
| 07/24/2003 | US20030138434 Containing an immunogen, a first adjuvant functioning as a directing molecule and a second adjuvant functioning as a stimulant which are chemically distinct |
| 07/24/2003 | US20030138433 Contacting isolated B-cell in vitro with a target antigen conjugate to produce target antigen manipulated B cells, fusing manipulated cells into the subject |
| 07/24/2003 | US20030138430 Drug combinations containing an agent that arrests target cells in the G2 (cell enlargement) and/or M phase (DNA replication) of the cell cycle and another drug that targets an internalising cell surface structure e.g. an antigen |
| 07/24/2003 | US20030138429 Compositions and methods for inhibiting metastasis |
| 07/24/2003 | US20030138423 Antiinflammation agents and immunotherapy using an enzyme inhibitor; sepsis; antiarthritic and - ulcer agents; colitis; myocarditis; glomerulonephritis; gastrointestinal and nervous system disorders; Crohn's disease; automimmune |
| 07/24/2003 | US20030138422 Antibodies against growth and differentiation factor-8 (GDF-8), also known as myostatin, including fragments; muscle and bone degenerative disorders; muscular dystropy/atrophy; antidiabetic agents; congestive obstructive pulmonary disease |
| 07/24/2003 | US20030138421 Human Antibodies specific for interleukin 15 (IL-15) |
| 07/24/2003 | US20030138417 Comprising a succinate of histadine buffer having pH from 5.5-6.5, polysorbate, and a tonicity modifier to contribute to the isotonicity, e.g., NaCl or MgCl2; storage stability of 1-2 years; antiagglomerants |
| 07/24/2003 | US20030138413 Activating dendritic cells from the host which are rendered hyporesponsive to activation stimuli by the disease by administering a tumor-derived DC inhibitory factor antagonist in combination with a Toll-like receptor agonist |
| 07/24/2003 | US20030138410 Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| 07/24/2003 | US20030138399 Anti-inflammatory therapy for inflammatory mediated infection |
| 07/24/2003 | CA2841097A1 Albumin fusion proteins |
| 07/24/2003 | CA2474002A1 Bispecific antibody dna constructs for intramuscular administration |
| 07/24/2003 | CA2473570A1 Antisense compounds directed against human csf-1 |
| 07/24/2003 | CA2473416A1 Oral vaccination |
| 07/24/2003 | CA2473039A1 Novel anti-igf-ir antibodies and uses thereof |
| 07/24/2003 | CA2472579A1 Hiv vaccine and method of use |
| 07/24/2003 | CA2472468A1 Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| 07/24/2003 | CA2471907A1 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/24/2003 | CA2471702A1 Human monoclonal antibodies against cd30 |
| 07/24/2003 | CA2471513A1 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471363A1 Albumin fusion proteins |
| 07/24/2003 | CA2470421A1 Use of a novel cell surface protease from group b streptococcus |
| 07/24/2003 | CA2469715A1 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| 07/24/2003 | CA2464472A1 Antibody targeting compounds |
| 07/24/2003 | CA2463008A1 Efficient protein expression system |
| 07/23/2003 | EP1329507A1 Artificial protein having potentiated immunogenicity of epitope |
| 07/23/2003 | EP1329459A2 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| 07/23/2003 | EP1329226A2 Hapten-Carrier Conjugates for use in Drug Abuse Therapy |
| 07/23/2003 | EP1328816A2 Regulation of neutral development by daedalos |
| 07/23/2003 | EP1328662A2 Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328646A2 Regulation of human adenylate cyclase, type iv |
| 07/23/2003 | EP1328641A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 07/23/2003 | EP1328640A2 Polypeptides and polynucleotides from haemophilus influenzae and their use |
| 07/23/2003 | EP1328635A2 Compositions and methods relating to lung specific genes |
| 07/23/2003 | EP1328631A2 Her-2/neu fusion proteins |
| 07/23/2003 | EP1328630A2 Secreted proteins |
| 07/23/2003 | EP1328625A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 07/23/2003 | EP1328549A1 Human prostate specific g-protein receptor hpraj70 |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328543A2 Nucleic acids and proteins from streptococcus groups a & b |
| 07/23/2003 | EP1328542A1 Von willebrand factor-binding proteins from staphylococci |
| 07/23/2003 | EP1328541A2 Basb207 polypeptides and polynucleotides from nontypeable haemophilus influenzae |
| 07/23/2003 | EP1328540A2 Immunoreactive peptidic ctl epitopes of human cytomegalovirus pp150 |
| 07/23/2003 | EP1328320A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 07/23/2003 | EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof |
| 07/23/2003 | EP1328293A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 07/23/2003 | EP1328292A2 Immunogenic compositions comprising liver stage malarial antigens |
| 07/23/2003 | EP1328289A2 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof |
| 07/23/2003 | EP1328287A1 Compositions and methods for wt1 specific immunotherapy |
| 07/23/2003 | EP1328255A1 Composition and method for stable injectable liquids |
| 07/23/2003 | EP1154785B1 Inhibitors for use in hemostasis and immune function |
| 07/23/2003 | EP0914166B1 Methods of terminal sterilization of biological products |
| 07/23/2003 | EP0873137B1 Compositions including calcium influx blockers for inhibiting cell growth |
| 07/23/2003 | EP0855919B1 Induction of mucosal immune responses by vitamin d3 and antigen-encoding dna complexe to cationic lipid |
| 07/23/2003 | EP0814827B1 Vascular endothelial growth factor-b |
| 07/23/2003 | EP0756630B1 Recombinant pgp3, methods of preparation and use in diagnosis and therapy |
| 07/23/2003 | EP0670905B1 Recombinant viruses displaying a nonviral polypeptide on their external surface |
| 07/23/2003 | EP0643770B1 Helicobacter pylori cytotoxin associated immunodominant antigen useful for vaccines and diagnostics |